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Abstract  The  treatment  of  cutaneous  melanoma  has  historically  been  essentially  surgical.
Much progress  has  been  made  in  this  area,  and  the  resection  margins  have  been  established
based on  tumour  depth.  Candidates  are  also  identiﬁed  for  lymphadenectomy,  avoiding  the
morbidity  of  the  procedure  in  patients  who  do  not  require  it.  But  little  progress  has  been
made in  systemic  treatment,  since  the  70’s  when  the  use  of  dacarbazine  was  introduced  for
the treatment  of  patients  with  tumour  progression  or  distant  metastasis,  with  disappointing
results.  Despite  this,  dacarbazine  has  been  the  most  used  drug  to  the  present.
Three years  ago,  two  new  drugs  were  introduced,  one  of  them  based  on  the  target  therapy
and other  one  in  the  immunotherapy,  offering,  with  the  obtained  results,  an  alternative  in  the
treatment  of  cutaneous  melanoma.
The  objectives  of  this  article  are  to  show  the  pathways  of  these  drugs,  to  describe  the  current
role of  surgery  in  cutaneous  melanoma,  with  the  arrival  of  these  drugs,  as  well  as  to  know
the therapeutic  alternatives  that  are  emerging  for  the  cutaneous  melanoma  based  on  scientiﬁc
evidence.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Published  by  Masson  Doyma  México  S.A.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).PALABRAS  CLAVE La  cirugía  en  melanoma  cutáneo  maligno  y  las  nuevas  drogas
Melanoma;
Tratamiento  de
melanoma
Resumen  El  tratamiento  del  melanoma  cutáneo  ha  sido,  históricamente,  esencialmente
quirúrgico.  Muchos  progresos  se  han  hecho  en  esta  área:  se  han  establecido  los  márgenes  de
resección con  base  en  la  profundidad  del  tumor  y,  se  han  identiﬁcado  pacientes  candidatos  a
linfadenectomía,  evitando  así  la  morbilidad  del  procedimiento  en  pacientes  que  no  la  requieren.
 Please cite this article as: Nieweg OE, Gallegos-Hernández JF. La cirugía en melanoma cutáneo maligno y las nuevas drogas. Cir Cir.
2015; 83: 175--180.
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176  O.E.  Nieweg,  J.F.  Gallegos-Hernández
Pero  en  el  tratamiento  sistémico  se  han  hecho  escasos  progresos:  desde  los  an˜os  setenta  se
introdujo el  uso  de  la  dacarbazina  para  el  tratamiento  de  los  pacientes  con  progresión  tumoral
o metástasis  sistémicas,  pero  los  resultados  han  sido  decepcionantes;  a  pesar  de  ello,  la  dacar-
bazina ha  sido  la  droga  más  utilizada  hasta  la  actualidad.
Hace  3  an˜os,  2  nuevas  drogas  fueron  introducidas,  una  de  ellas  basada  en  la  terapia  blanco  y  la
otra en  la  inmunoterapia,  ofreciendo  una  alternativa  en  el  tratamiento  del  melanoma  cutáneo.
Los objetivos  de  este  manuscrito  son:  mostrar  las  vías  de  acción  de  estos  medicamentos.
Describir cuál  es  el  papel  actual  que  tiene  la  cirugía  en  el  tratamiento  del  melanoma  cutá-
neo con  la  llegada  de  estas  drogas,  y  conocer  qué  alternativas  terapéuticas  están  surgiendo
para el  tratamiento  sistémico  del  melanoma  cutáneo  con  base  en  la  evidencia  cientíﬁca.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Publicado  por  Masson  Doyma  México  S.A.  Este
es un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Targeted  therapy  is  related  to  the  tyrosine-kinase  pathway,
also  known  as  MAP  Kinase  pathway  or  MAPK  signalling  path-
way  (Fig.  1).  This  pathway  begins  in  the  cellular  membrane
EGF
Cell proliferation
RAS
B-raf 
MEK 
ERKackground
ince  1971,  dacarbazine  has  been  the  standard  treat-
ent  for  patients  with  systemic  inoperable  metastases
f  malignant  melanoma.1 It  produces  global  responses  in
pproximately  15%  of  patients,  but  in  only  4%  the  disease
isappears,  and  in  those  with  full  response  the  inter-
al  free  of  disease  is  very  short;  the  mean  recurrence  is
--6  months.
Recently,  a  great  variety  of  effective  drugs  for  the  treat-
ent  of  bronchogenic  cancer,  breast  cancer,  colorectal
ancer  and  other  tumours  have  appeared,  turning  the  treat-
ent  of  these  neoplasms  into  a  multidisciplinary  exercise;
hile  for  cutaneous  melanoma  the  treatment  is  still  within
he  ﬁeld  of  only  one  discipline:  surgery.
The  progress  in  the  treatment  of  other  neoplasms  has
ar  overtaken  that  of  melanoma.  Cutaneous  melanoma  has
roven  to  be,  more  than  other  neoplasms,  insensitive  to  the
arious  systemic  therapies  and  radiotherapy.  This  may  be
ue  to  the  fact  that  the  cells  from  which  melanoma  ori-
inates  are  designed  to  protect  it  against  the  damages  of
NA  caused  by  the  sun,  and  are  located  in  the  skin,  where
hey  are  exposed  to  the  damage  caused  by  UV  rays  on  the
NA.  These  cells  seem  to  have  the  ability  to  defend  them-
elves  when  exposed  to  cytotoxic  drugs,  similarly  to  how
hey  do  in  the  hostile  environment  where  they  normally
evelop.
This  does  not  mean  that  there  have  been  no  develop-
ents  in  the  therapy  of  cutaneous  melanoma;  substantial
evelopments  have  been  made  in  the  understanding  of
he  behaviour  of  this  neoplasm  and  its  surgical  treatment.
esection  margins  were  substantially  reduced  based  on  solid
cientiﬁc  evidence;  it  was  proved  that  prophylactic  lymph
ode  dissection  and  regional  perfusion  were  not  useful  and
hese  were  abandoned;  lymphatic  mapping  with  biopsy  of
entinel  lymph  node  was  introduced,  and  it  was  proved  that
t  improved  staging,  which  offered  valuable  information  for
he  prognosis,  which  in  selected  patients  avoided  unneces-
ary  morbidity  caused  by  lymph  node  dissection,  and  that
t  improved  the  survival  of  patients  with  a  positive  sentinel
ymph  node.2
F
o
aIn  the  staging  and  diagnosis,  it  was  proved  that  positron
mission  tomography  improved  the  staging  of  patients
ith  advanced  disease.  As  a  result  of  these  develop-
ents,  the  treatment  of  malignant  melanoma  became
ore  individualised  and  survival  rates  improved;  however,
elanoma  experts  are  still  waiting  for  a  really  effective
rug  for  the  systemic  treatment  of  patients  with  systemic
isease.
Changes  arrived  in  2010,  when  there  were  2  relevant
evelopments  in  systemic  therapy:  targeted  therapy  and
mmunotherapy.
argeted therapyigure  1  The  tyrosine-kinase  pathway  begins  in  the  receptor
f the  epidermal  growth  factor  (EGF)  of  the  cellular  membrane
nd goes  through  a  series  of  steps  towards  the  nucleus.
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Dendritic cell
Antigen
CTLA-4
T lymphocyte
Figure  2  Dendritic  cells  present  the  antigen  for  melanoma  to
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and  follows  several  steps  until  reaching  the  nucleus.  The
receptor  of  the  epithelial  development  factor  receives  the
signal  to  stimulate  the  development  and  activate  the  RAS
protein.  The  RAS  protein  activates  the  B-Raf  protein,  which
in  turn  activates  the  MEK  protein  (also  known  as  MAPK),
which  makes  the  ERK  stimulate  the  genes  in  the  nucleus
that  are  responsible  for  cellular  development  and  prolifera-
tion.  This  is  a  physiological  process  responsible  for  cellular
proliferation  when  necessary,  and  which  stops  when  it  is  not
necessary.
The  problem  arises  where  there  is  a  mutation  in  the  gene
that  is  responsible  for  producing  the  B-Raf  protein.  In  the
DNA  chain,  an  adenine  is  replaced  with  a  thiamine;  as  a  con-
sequence,  a  valine  amino  acid  of  the  B-Raf  protein  sequence
is  replaced  with  glutamic  acid  in  the  600  codon  amino  acid;
this  is  the  origin  of  the  name  of  the  V600E  mutation.  The
result  is  a  B-Raf  aberrant  protein  which  loses  the  ability  to
‘‘turn  off’’  or  ‘‘stop’’,  and  this  translates  into  persistence  of
stimulation  of  MEK,  and  this,  in  turn,  continues  to  stimulate
the  ERK,  which  stimulates  the  genes  that  perpetuate  cellular
proliferation;  the  end  result  is  a  cancerous  cell  which  con-
tinues  to  divide.  The  mutation  of  the  BRAF  gene  is  present
in  half  of  all  melanomas.
A  small  molecule  called  vemurafenib  joins  the  malicious
B-Raf  V600E  protein  and  makes  it  ineffective,  the  cellular
proliferation  stops  and  tumour  cells  go  into  apoptosis.
Several  studies  proved  that  this  molecule  is  effec-
tive  against  cutaneous  melanoma;  a  phase  III  clinical  trial
which  included  675  patients  with  inoperable  stages  IIIC
and  IV  melanoma  who  had  B-Raf  V600E  mutation  and
vemurafenib  was  compared  with  dacarbazine;  an  interme-
diate  analysis  was  published  after  a  mean  follow-up  of  3.8
months  of  patients  in  the  vemurafenib  group.3 The  response
was  impressive  in  the  vemurafenib  +  dacarbazine  group  vs.
dacarbazine  only:  48%  vs.  5%  (p  <  0.001).
Responses  to  vemurafenib  are  very  fast,  and  some
patients  feel  an  improvement  a  few  days  after  start-
ing  treatment.  In  this  study,  2  patients  had  full  response
(0.9%),  with  a  survival  mean  of  9.2  months  in  the
experimental  arm  and  7.4  months  in  the  control  arm;
patients  obtained  an  improvement  in  overall  survival  of
7  weeks.
Unfortunately,  the  responses  are  not  lasting;  the  mean
duration  of  the  response  is  6  months  and,  with  rare  excep-
tions,  all  patients  eventually  relapse  or  progress.
At  The  Netherlands  Cancer  Institute,  more  than  100
patients  received  this  treatment  and  only  one  had  an  inter-
val  free  of  disease  of  1.5  years.
The  problem  is  that  melanoma  quickly  becomes  resistant
to  vemurafenib  and  develops  several  pathways  to  block  its
effect.
Vemurafenib  is  associated  to  important  morbidity,  such
as  photosensitivity,  arthralgia,  rash,  fatigue,  alopecia
and  an  easier  development  of  dermic  neoplasms,  mainly
keratoacanthoma  and  epidermoid  carcinoma.  The  exten-
sive  side  effects  of  vemurafenib  show  that  it  not  only
affects  neoplastic  cells  and  that  the  connotation  ‘‘targeted
therapy’’  may  be  an  exaggeration;  in  Mexico,  the  results
with  the  treatment  of  patients  with  cutaneous  melanoma
with  vemurafenib  are  still  to  be  reported;  in  the  United
States  of  America  the  cost  of  the  treatment  with  this  medi-
cation  is  US$9400  a  month.
t
t cells.
mmunotherapy
endritic  cells  present  the  antigen  of  melanoma  to  T  lym-
hocytes  (Fig.  2);  these  reach  the  tumour  and  kill  neoplastic
ells.  Once  the  immune  response  is  activated,  dendritic  cells
ctivate  cytotoxic  T  lymphocytes  associated  to  the  cytotoxic
-lymphocyte-associated  protein  4  (CTLA-4);  these  have  the
ole  of  regulating  the  activity  of  the  immune  response  in  the
ense  that  they  decrease  the  activity  of  T  cells  and  their  pro-
iferation  (Fig.  3).  This  is  a  physiological  mechanism  which
revents  the  immune  response  from  over-activating  and  pre-
ents  the  immune  system  from  attacking  the  tissues  of  the
rganism;  CTLA-4  creates  a balance  in  the  activity  of  the
mmune  response.
The other  new  drug  is  ipilimumab,  a  human  monoclonal
ntibody  which  ﬁxes  to  the  CTLA-4.  Ipilimumab  blocks  CTLA-
 and  prevents  it  from  activating  (Fig.  4);  in  other  words,
t  removes  the  brake  that  an  activated  CTLA-4  applies  to
he  immune  response,  and  as  a  result  the  immune  response
ncreases.
Ipilimumab  does  not  attack  the  cells  of  the  melanoma
irectly,  which  is  why  it  is  not  a  targeted  therapy  as
emurafenib,  but  rather  stimulates  the  immune  response
n  general,  including  the  existing  immune  response  against
elanoma.
In  a  phase  III  study,4 502  patients  were  randomised
ith  stages  III  and  IV  metastatic  inoperable  melanoma  in  2
roups;  one  received  ipilimumab  plus  dacarbazine,  and  the
ther  dacarbazine  plus  placebo.  The  response  was  15%  in
he  group  of  ipilimumab  and  10%  in  the  control  group;  this
ifference  was  not  signiﬁcant.
In  contrast  to  vemurafenib,  which  acts  fast,  the  response
o  ipilimumab  is  slow,  it  takes  approximately  3  months  to
ecome  evident;  there  may  even  be  a period  when  the
umour  grows,  and  this  happens  when  T  lymphocytes  inﬁl-
rate  the  tumour.
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CTLA-4
Antigen Weakens immune
response
Figure  3  Once  the  immune  response  is  initiated,  the  dendritic  cell  activates  T-cytotoxic  lymphocytes  associated  to  the  antigen
(CTLA-4). CTLA-4  inhibits  the  immune  response.
CTLA-4
Ipilimumab 
Antigen
Increased
immune
response
Figure  4  The  ipilimumab  monoclonal  antibody  blocks  the
CTLA-4.  This  stops  the  inhibitory  effect  of  CTLA-4  and  stimulates
t
g
(
r
r
v
9
d
d
t
t
t
i
t
d
D
V
f
e
h
w
a
i
w
0
i
m
s
w
l
n
a
d
t
a
d
b
t
n
t
m
t
a
t
t
m
In the  past,  35%  of  patients  with  stages  III  and  IVhe immune  response.
In  the  study  mentioned,  4  patients  in  the  ipilimumab
roup  had  full  response  (1.6%)  and  2  in  the  control  group
0.8%),  global  survival  was  signiﬁcantly  better  in  the  group
eceiving  ipilimumab  plus  dacarbazine  than  in  the  group
eceiving  dacarbazine  plus  placebo  after  3  years:  21%
s  12%  (p  <  0.001);  ipilimumab  increased  the  survival  by
 weeks.
This  treatment  causes  serious  morbidity,  especially  in  the
igestive  tract;  56%  of  patients  treated  with  ipilimumab  plus
acarbazine  presented  grade  3  or  4  toxicity  related  with
he  immune  response;  there  were  no  deaths  related  to  the
reatment  or  gastrointestinal  perforations  in  the  experimen-
al  group,  but  a  previous  study5 had  previously  reported
ntestinal  perforations  and  2.1%  mortality  associated  to  the
reatment;  in  the  United  States  of  America  the  price  of  the
rug  is  $120,000  dollars  for  4  doses.
m
h
tiscussion
emurafenib  and  ipilimumab  have  logically  made  all  pro-
essionals  dedicated  to  melanoma  around  the  world  be
xpectant.  Are  these  2  original  drugs,  the  great  advance  we
ave  been  waiting  for  many  years?
In  our  opinion,  the  response  is  ambiguous:  yes  and  no;
e  would  be  tempted  to  say  no  because  these  2  drugs
re  not  necessarily  the  great  advance  we  have  been  wait-
ng  for;  neither  patients  nor  their  doctors  are  too  thrilled
hen  they  are  told  that  the  full  response  ranges  from
.9  to  1.6%,  or  when  they  are  told  that  survival  may  be
ncreased  by  a few  months  at  the  expense  of  a considerable
orbidity.
To  make  these  percentages  familiar  in  a  perspective  that
urgeons  are  more  familiarised  with:  lymphatic  mapping
ith  biopsy  of  the  sentinel  lymph  node,  with  subsequent
ymph  node  dissection  in  the  event  of  positive  sentinel  lymph
ode,  improves  full  response  in  19%  and  for  at  least  10  years,
 percentage  of  a  different  magnitude  than  that  offered  by
rugs.
Vemurafenib  and  ipilimumab  must  not  be  viewed  with
he  same  suspicion  as  previous  drugs  promoted  as  the  great
dvance  in  the  treatment  of  melanoma,  since  these  2  new
rugs  are  revolutionary  at  the  basic  science  level.
Vemurafenib  acts  near  the  genetic  mutation,  which  is  the
asis  of  the  alteration  in  the  neoplastic  cell;  unfortunately,
he  correction  of  the  defect  in  only  one  aberrant  gene  is
ot  enough  to  stop  the  proliferation  of  melanoma  for  more
han  a  few  months.  There  are  more  than  30,000  genetic
utations  in  the  melanoma  cell.  Are  there  patterns  of  muta-
ions  and  genetic  aberrations  we  may  block?  Researchers
re  working  on  new  drugs  acting  at  different  levels  of  the
yrosine-kinase  pathway,  the  combination  of  dabrafenib  and
rametinib  act  both  on  B-Raf  as  on  MEK;  this  seems  to  be  the
ost  promising  approach.elanoma  had  a  survival  of  one  year.  This  percentage
as  improved  to  76%  with  the  combined  regime6;  maybe
his  combination  may  have  the  sustained  effect  that
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vemurafenib  is  lacking  and  may  avoid  melanoma  from
becoming  resistant  so  quickly.
Relation  of  the  metastatic  surgery  and  vemurafenib
This  drug  is  of  great  relevance  and  importance  for  sur-
geons.  The  response  it  causes  offers  an  interesting  chance
for  patients  with  large  growth  of  non-resectable  metastatic
tumours  with  mutation  of  V600  BRAF:  half  of  patients
respond,  and  although  most  do  not  have  a  full  response  and
the  response  does  not  last,  the  speed  of  the  response  may
offer  an  advantage  in  the  time  to  operate  and  resect  an
initially  inoperable  tumour  which,  due  to  the  response  to
the  treatment,  can  be  removed  before  it  becomes  resistant
and  begins  to  grow  again;  this  phenomenon  of  downstaging
seems  to  be  an  attractive  option  for  patients  with  inoperable
tumours  at  the  beginning  of  the  treatment,  and  may  be  an
alternative  to  improve  survival  in  patients  with  metastatic
melanoma,  mainly  in  M1A  and  M1B  stages.
The  weakness  of  ipilimumab  is  that  it  is  not  speciﬁc
for  melanoma  and  stimulates  the  immune  response  in  gen-
eral.  The  true  importance  of  ipilimumab  is  the  long  term
beneﬁt  for  patients  showing  response  or  stability  of  the  dis-
ease.  The  follow-up  of  cohorts  of  patients  has  proven  that
the  full  response  may  continue  in  some  patients  beyond  6
years.  The  impression  is  that  survival  to  5  years  may  be  20%.
Many  patients  may  have  stable  metastases  and  coexist  for
some  time  with  their  metastatic  disease;  this  is,  having  a
‘‘chronic’’  oncologic  disease.
Conclusion
Cutaneous  melanoma  has  always  been  a  surgical  and  largely
monodisciplinary  disease.  It  is  when  the  patient  presents
distant  metastases  that  he  or  she  was  sent  to  systemic
treatment,  dacarbazine  was  administrated,  and  the  initially
treating  physician  never  saw  the  patient  again.  This  has
changed,  currently  there  is  targeted  therapy,  immunother-
apy,  adjuvant  treatments  and  rescue  surgery  after  almost
successful  systemic  treatments;  there  is  currently  a  direct
interaction  between  the  medical  oncologist  and  surgi-
cal  oncologist.  The  treatment  of  melanoma  has  therefore
become  multidisciplinary.
Will  the  new  treatments  change  our  surgical  strategy  in
cutaneous  melanoma?  First  we  have  to  wait  for  long  term
results  to  know  the  real  value  of  these  drugs;  we  still  remem-
ber  studies  of  new  drugs  which  showed  improvements  in  the
beginning,  only  to  see  that  beneﬁt  disappear  after  long  term
follow-up.7--9 We  also  have  to  wait  to  know  the  potential  side
effects  which  may  be  seen  after  a  longer  follow-up  period.
What  would  happen  if  these  successful  new  drugs  were
tested  in  early  stages  of  melanoma?  In  an  adjuvant  man-
ner  after  dissection  of  lymph  nodes  for  palpable  disease  for
instance,  but  also----and  why  not?----in the  cases  of  patients
with  metastatic  sentinel  lymph  nodes,  and  even  in  patients
with  localised  disease  but  known  to  have  a  bad  prognosis,
such  as  thick  and  ulcerated  melanomas,  which  are  those
more  frequently  diagnosed  in  Mexico;  studies  which  require,
without  a  doubt,  surgical  support.
Many  surgeons  wonder  if  patients  with  cutaneous
melanoma  will  be  treated  in  the  near  future  with  systemic
6179
herapy  instead  of  surgery.  We  think  this  is  unlikely,  and  will
ontinue  to  operate  patients  with  stages  iii  and  iv  melanoma
ith  resectable  lesions;  after  all,  no  melanoma  is  resistant
o  formaldehyde.
The  surgical  treatment  of  patients  with  stages  iiiand  iv
perable  melanomas  offers  a  survival  of  up  to  10  years
or  35%,  substantially  better  than  any  optimistic  survival
e  may  achieve  with  any  drug.  The  new  drugs  may  even
enerate  patients  as  candidates  for  surgery  who  were  not
o  upon  diagnosis,  such  as  patients  with  initially  inop-
rable  metastatic  melanomas,  which  become  resectable
fter  neoadjuvant  systemic  therapy,  and  stage  IV  patients
ho  require  clean  up  surgeries  after  successful  systemic
reatment;  that  multidisciplinary  treatment  may  cause  a
rowth  in  the  number  of  patients  with  melanoma  requiring
urgery.
These  are  interesting  times  for  professionals  interested
n  cutaneous  melanoma.  The  arrival  of  targeted  therapy
nd  immunotherapy  improved  the  survival  of  patients  with
dvanced  disease.  Although  full  responses  are  rare,  these
atients  have  to  be  evaluated  in  a  multidisciplinary  manner.
lso,  the  basis  of  the  new  drugs  does  not  seem  to  be  very
mpressive;  however,  a  better  understanding  of  the  molec-
lar  biology  of  the  tumour  and  the  immune  system  allow
or  the  development  of  even  more  innovative  drugs  aimed
peciﬁcally  at  the  tumour  or  stimulating  the  immune  system
gainst  the  neoplasm.
The  future  had  never  been  so  bright  in  the  therapeutic
cenario  of  cutaneous  melanoma,  and  we  must  be  prepared
o  see  the  succession  of  amazing  and  wonderful  events  in
ears  to  come.
Surgeons  can  and  will  play  an  important  role  in  the  future
reatment  of  melanoma  and  in  research.  Surgeons  around
he  world  must  be  encouraged  to  participate  in  studies  to
dvance  the  ﬁeld  of  treatment  of  melanoma  and  make  the
ost  of  the  advances  made  so  far.
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